Co-Administration of an Excipient Oligonucleotide Helps Delineate Pathways of Productive and Nonproductive Uptake of Phosphorothioate Antisense Oligonucleotides in the Liver

Nucleic Acid Therapeutics

Volumn 27, Issue 4, 2017, Pages 209-220

  Donner, Aaron J ^a   Wancewicz, Edward V ^a   Murray, Heather M ^a   Greenlee, Sarah ^a   Post, Noah ^a   Bell, Melanie ^a   Lima, Walt F ^a   Swayze, Eric E ^a   Seth, Punit P ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

ASGR; hepatocytes; nonparenchymal cells; phosphorothioate; productive uptake; Stabilin 2

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ASIALOGLYCOPROTEIN RECEPTOR; ASIALOGLYCOPROTEIN RECEPTOR 1; CELL SURFACE RECEPTOR; CHOLESTEROL; EXCIPIENT OLIGONUCLEOTIDE; GLUCAGON RECEPTOR; GLYCOSAMINOGLYCAN POLYSULFATE; LOW DENSITY LIPOPROTEIN RECEPTOR; OLIGONUCLEOTIDE; PHOSPHOROTHIOATE ANTISENSE OLIGONUCLEOTIDE; PHOSPHOROTHIOIC ACID; SCAVENGER RECEPTOR A; SCAVENGER RECEPTOR BI; STABILIN 2; TOCOPHEROL; UNCLASSIFIED DRUG; EXCIPIENT; NERVE CELL ADHESION MOLECULE; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; STAB2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BOLUS INJECTION; CELL ACTIVITY; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG INFUSION; DRUG POTENTIATION; ENDOTHELIUM CELL; LIVER CELL; LIVER PARENCHYMA; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; NONPARENCHYMAL CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; COCULTURE; CYTOLOGY; DRUG EFFECTS; LIVER; MALE; METABOLISM; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; CELL ADHESION MOLECULES, NEURONAL; CELL LINE, TUMOR; COCULTURE TECHNIQUES; ENDOTHELIAL CELLS; EXCIPIENTS; HEPATOCYTES; LIVER; MALE; MICE, INBRED BALB C; MICE, INBRED C57BL; OLIGONUCLEOTIDES, ANTISENSE; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; TISSUE DISTRIBUTION;

EID: 85026666222     PISSN: 21593337     EISSN: 21593345     Source Type: Journal    
DOI: 10.1089/nat.2017.0662     Document Type: Article

References (36)

1. Bennett CF and EE Swayze. (2010). RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 50:259-293.
2. Bennett CF. (2007). Pharmacological properties of 2'-Omethoxyethyl-modified oligonucleotides. In: Antisense Drug Technology: Principles, Strategies and Applications. 2nd edn. Crooke ST, ed. CRC Press, Boca Raton, pp 273-304.
3. Eckstein F. (2014). Phosphorothioates, essential components of therapeutic oligonucleotides. Nucleic Acid Ther 24:374-387.
4. Brown DA, SH Kang, SM Gryaznov, L DeDionisio, O Heidenreich, S Sullivan, X Xu and MI Nerenberg. (1994). Effect of phosphorothioate modification of oligodeoxy nucleotides on specific protein binding. J Biol Chem 269:26801-26805.
5. Liang X-H, H Sun, W Shen and ST Crooke. (2015). Identification and characterization of intracellular proteins that bind oligonucleotides with phosphorothioate linkages. Nucleic Acids Res 43:2927-2945.
6. Vickers TA and ST Crooke. (2016). Development of a quantitative BRET affinity assay for nucleic acid-protein interactions. PLoS One 11:e0161930.
7. Beltinger C, HU Saragovi, RM Smith, L LeSauteur, N Shah, L DeDionisio, L Christensen, A Raible, L Jarett and AM Gewirtz. (1995). Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J Clin Invest 95:1814-1823.
8. MillerCM,AJ Donner,EEBlank,AWEgger,BMKellar,ME Ostergaard, PP Seth and EN Harris. (2016). Stabilin-1 and Stabilin-2 are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides (ASOs) in the liver. Nucleic Acids Res 44:2782-2794.
9. Geary RS, E Wancewicz, J Matson,MPearce, A Siwkowski, EE Swayze and CF Bennett. (2009). Effect of dose and plasma concentration on liver uptake and pharmacologic activity of a 2'-methoxyethyl modified chimeric antisense oligonucleotide targeting PTEN. Biochem Pharmacol 78: 284-291.
10. Koller E, TM Vincent, A Chappell, S De, M Manoharan and CF Bennett. (2011). Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res 39:4795-4807.
11. Graham MJ, ST Crooke, DK Monteith, SR Cooper, KM Lemonidis, KK Stecker, MJ Martin and RM Crooke. (1998). In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration. J Pharmacol Exp Ther 286:447-458.
12. Sehgal A, A Vaishnaw and K Fitzgerald. (2013). Liver as a target for oligonucleotide therapeutics. J Hepatol 59:1354-1359.
13. Graham MJ, ST Crooke, KM Lemonidis, HJ Gaus, MV Templin and RM Crooke. (2001). Hepatic distribution of a phosphorothioate oligodeoxynucleotide within rodents following intravenous administration. Biochem Pharmacol 62:297-306.
14. Liu W, Y Hou, H Chen, H Wei, W Lin, J Li, M Zhang, F He and Y Jiang. (2011). Sample preparation method for isolation of single-cell types from mouse liver for proteomic studies. Proteomics 11:3556-3564.
15. Shemesh CS, RZ Yu, HJ Gaus, S Greenlee, N Post, K Schmidt, MT Migawa, PP Seth, TA Zanardi, et al. (2016). Pharmacokinetic and pharmacodynamic investigations of ION-353382, a model antisense oligonucleotide: Using alpha-2-macroglobulin and murinoglobulin double-knockout mice. Nucleic Acid Ther 26:223-235.
16. Yu RZ, B Baker, A Chappell, RS Geary, E Cheung and AA Levin. (2002). Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma. Anal Biochem 304:19-25.
17. Murray S,DIttig,EKoller,ABerdeja,AChappell, TP Prakash, M Norrbom, EE Swayze, CJ Leumann and PP Seth. (2012). TricycloDNA-modified oligo-2'-deoxyribonucleotides reduce scavenger receptor B1 mRNA in hepatic and extra-hepatic tissues-a comparative study of oligonucleotide length, design and chemistry. Nucleic Acids Res 40:6135-6143.
18. Seth PP, G Vasquez, CA Allerson, A Berdeja, H Gaus, GA Kinberger, TP Prakash,MTMigawa,BBhat and EE Swayze. (2010). Synthesis and biophysical evaluation of 2',4'-constrained 2'O-methoxyethyl and 2',4'-constrained 2'Oethyl nucleic acid analogues. J Org Chem 75:1569-1581.
19. Seth PP, A Siwkowski, CR Allerson, G Vasquez, S Lee, TP Prakash, EV Wancewicz, D Witchell and EE Swayze. (2009). Short antisense oligonucleotides with novel 2'-4' conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. J Med Chem 52:10-13.
20. Henry SP, RS Geary, R Yu and AA Levin. (2001). Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors? Curr Opin Investig Drugs 2:1444-1449.
21. Crooke ST, MJ Graham, JE Zuckerman, D Brooks, BS Conklin, LL Cummins, MJ Greig, CJ Guinosso, D Kornbrust, et al. (1996). Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J Pharmacol Exp Ther 277:923-937.
22. Nishina K, W Piao, K Yoshida-Tanaka, Y Sujino, T Nishina, T Yamamoto, K Nitta, K Yoshioka, H Kuwahara, et al. (2015). DNA/RNA heteroduplex oligonucleotide for highly efficient gene silencing. Nat Commun 6:7969.
23. Wolfrum C, S Shi, KN Jayaprakash, M Jayaraman, G Wang, RK Pandey, KG Rajeev, T Nakayama, K Charrise, et al. (2007). Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 25:1149-1157.
24. Butler M, RM Crooke, MJ Graham, KM Lemonidis, M Lougheed, SF Murray, D Witchell, U Steinbrecher and CF Bennett. (2000). Phosphorothioate oligodeoxynucleotides distribute similarly in class A scavenger receptor knockout and wild-type mice. J Pharmacol Exp Ther 292:489-496.
25. Harris EN and PH Weigel. (2008). The ligand-binding profile of HARE: hyaluronan and chondroitin sulfates A, C, and D bind to overlapping sites distinct from the sites for heparin, acetylated low-density lipoprotein, dermatan sulfate, and CS-E. Glycobiology 18:638-648.
26. Pandey MS, EN Harris, JA Weigel and PH Weigel. (2008). the cytoplasmic domain of the hyaluronan receptor for endocytosis (HARE) contains multiple endocytic motifs targeting coated pit-mediated internalization. J Biol Chem 283:21453-21461.
27. Pempe EH, Y Xu, S Gopalakrishnan, J Liu and EN Harris. (2012). Probing structural selectivity of synthetic heparin binding to stabilin protein receptors. J Biol Chem 287: 20774-20783.
28. Steirer LM, EI Park, RR Townsend and JU Baenziger. (2009). The asialoglycoprotein receptor regulates levels of plasma glycoproteins terminating with sialic acid a2,6-galactose. J Biol Chem 284:3777-3783.
29. Nair JK, JLWilloughby,AChan,KCharisse,MRAlam,Q Wang, M Hoekstra, P Kandasamy, AV Kel'in, et al. (2014). Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAimediated gene silencing. J Am Chem Soc 13:16958-16961.
30. Prakash TP, MJ Graham, J Yu, R Carty, A Low, A Chappell, K Schmidt, C Zhao, M Aghajan, et al. (2014). Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res 42:8796-8807.
31. Bijsterbosch MK, M Manoharan, ET Rump, RL De Vrueh, R van Veghel, KL Tivel, EA Biessen, CF Bennett, PD Cook and TJ van Berkel. (1997). In vivo fate of phosphorothioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial liver cells. Nucleic Acids Res 25:3290-3296.
32. Falkowska-Hansen B, M Falkowski, P Metharom, D Krunic and S Goerdt. (2007). Clathrin-coated vesicles form a unique net-like structure in liver sinusoidal endothelial cells by assembling along undisrupted microtubules. Exp Cell Res 313:1745-1757.
33. Knolle P. (2007). Role and function of liver sinusoidal endothelial cells. In: Liver Immunology, ME Gershwin, J Vierling, and M Manns, eds. Humana Press, Totowa, NJ, pp 25-39.
34. Yu RZ, KM Lemonidis, MJ Graham, JE Matson, RM Crooke, DL Tribble, MK Wedel, AA Levin, and RS Geary. (2009). Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. Biochem Pharmacol 77: 910-919.
35. Kinberger GA, TP Prakash, J Yu, G Vasquez, A Low, A Chappell, K Schmidt, HM Murray, H Gaus, EE Swayze and PP Seth. (2016). Conjugation of mono and di-GalNAc sugars enhances the potency of antisense oligonucleotides via ASGR mediated delivery to hepatocytes. Bioorg Med Chem Lett 26:3690-3693.
36. Schmidt K, TP Prakash, AJ Donner, GA Kinberger, HJ Gaus, A Low, ME Ostergaard, M Bell, EE Swayze and PP Seth. (2017). Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor. Nucleic Acids Res DOI: 10.1093/nar/gkx060